skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the management of symptoms in schizophrenia: focus on amisulpride

Review

(3151) Views  (933) Full article downloads

Authors: Ann M Mortimer

Published Date May 2009 Volume 2009:5 Pages 267 - 277
DOI: http://dx.doi.org/10.2147/NDT.S3949

Ann M Mortimer

Department of Psychiatry, Hertford Building, The University of Hull, Cottingham Road, Hull HU6 7RX, United Kingdom

Abstract: Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests with the treating clinician to employ a rational psychopharmacological approach towards the individual patient: there will be few circumstances in which amisulpride will not be a likely contender as a treatment choice.

Keywords: amisulpride, negative symptoms, clozapine, depression

 






Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
Biomimetic nanoparticles: preparation, characterization and biomedical applications
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
ABO and rhesus blood group distribution in Kurds
Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum